Physiologically-Based Pharmacokinetic Models for Optimal Drug Dosing in Children
Physiologically-Based Pharmacokinetic Models for Optimal Drug Dosing in Children
批准号:
9310077
负责人:
Michael Cohen-Wolkowiez
金额:
$56.65万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-01 至 2020-06-30
关键词:
AccountingAgeCaringCharacteristicsChildChild DevelopmentChildhoodClindamycinClinical DataClinical ResearchClinical TrialsClinical Trials DesignCollectionDataDevelopmentDoctor of PhilosophyDoseDrug usageEnrollmentEnvironmentGeneticGoalsIndividualInfectionInvestigational New Drug ApplicationLabelLegal patentMathematicsMedicalMethodologyModelingMonitorNational Institute of Child Health and Human DevelopmentPatientsPharmaceutical PreparationsPharmacologic SubstancePhysiologicalPhysiological ProcessesPhysiologyPopulationPrincipal InvestigatorProcessPropertyProtocols documentationPublic HealthPublishingRecording of previous eventsResearchResearch InfrastructureResearch InstituteResearch PersonnelSafetySample SizeSamplingScienceStaphylococcus aureusToxic effectTrainingTreatment FailureTrimethoprim-SulfamethoxazoleValidationbasedata managementdesigndrug developmenteffective therapyexperiencegenetic informationmathematical modelmembermodel developmentpharmacodynamic modelpharmacokinetic modelprospectivepublic health relevanceskillstool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The majority of off-patent drugs prescribed to children lack dosing information specific to this population, which can result in treatment failures and toxicities. Dosing information is lacking because clinical trials involving children pose specific challenges, among the most important of which is the large number of children required to estimate appropriate dosing at every stage of child development. Population physiologically based pharmacokinetic (PBPK) models are mathematical tools that incorporate changes of childhood, along with drug characteristics and genetic variances, to find the most appropriate dose for every pediatric age. By incorporating these factors, PBPK models can reduce the number of children needed for clinical trials. This proposal will systematically develop, and prospectively validate, population PBPK modeling in children.
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
External Evaluation of a Gentamicin Infant Population Pharmacokinetic Model Using Data from a National Electronic Health Record Database.
使用国家电子健康记录数据库的数据对庆大霉素婴儿群体药代动力学模型进行外部评估。
DOI:
10.1128/aac.00669-18
发表时间:
2018
期刊:
Antimicrobial agents and chemotherapy
影响因子:
4.9
作者:
[Ge,Shufan, Beechinor,RyanJ, Hornik,ChristophP, Standing,JosephF, Zimmerman,Kanecia, Cohen-Wolkowiez,Michael, Laughon,MatthewM, Clark,Reese, Gonzalez,Daniel]
通讯作者:
Gonzalez,Daniel
DOI:
10.1002/jcph.1053
发表时间:
2018-10
期刊:
Journal of clinical pharmacology
影响因子:
2.9
作者:
[Balevic SJ, Cohen-Wolkowiez M]
通讯作者:
Cohen-Wolkowiez M
Advances in pediatric pharmacology, therapeutics, and toxicology.
儿科药理学、治疗学和毒理学的进展。
DOI:
10.1016/j.yapd.2014.03.005
发表时间:
2014
期刊:
Advances in pediatrics
影响因子:
--
作者:
[Gonzalez,Daniel, Paul,IanM, BenjaminJr,DanielK, Cohen-Wolkowiez,Michael]
通讯作者:
Cohen-Wolkowiez,Michael
DOI:
10.1002/jcph.1116
发表时间:
2018-08
期刊:
Journal of clinical pharmacology
影响因子:
2.9
作者:
[Hornik CP, Gonzalez D, van den Anker J, Atz AM, Yogev R, Poindexter BB, Ng KC, Delmore P, Harper BL, Melloni C, Lewandowski A, Gelber C, Cohen-Wolkowiez M, Lee JH, Pediatric Trial Network Steering Committee]
通讯作者:
Pediatric Trial Network Steering Committee
DOI:
10.1007/s10928-018-9576-y
发表时间:
2018-06
期刊:
Journal of pharmacokinetics and pharmacodynamics
影响因子:
2.5
作者:
[Dallefeld SH, Atz AM, Yogev R, Sullivan JE, Al-Uzri A, Mendley SR, Laughon M, Hornik CP, Melloni C, Harper B, Lewandowski A, Mitchell J, Wu H, Green TP, Cohen-Wolkowiez M]
通讯作者:
Cohen-Wolkowiez M
共 6 条
RADx-UP CDCC SAY YES COVID Test Study
-
批准号:10366485
-
项目类别:
-
资助金额:$765.38万
-
财政年份:2020
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
RADx-UP CDCC
-
批准号:10844144
-
项目类别:
-
资助金额:$1272.91万
-
财政年份:2020
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
RADx-UP CDCC
-
批准号:10271490
-
项目类别:
-
资助金额:$3624.34万
-
财政年份:2020
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
RADx-UP CDCC
-
批准号:10439479
-
项目类别:
-
资助金额:$3236.41万
-
财政年份:2020
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
RADx-UP CDCC
-
批准号:10854638
-
项目类别:
-
资助金额:$200.0万
-
财政年份:2020
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
RADx-UP SAY YES COVID Test Study (S4)
-
批准号:10472985
-
项目类别:
-
资助金额:$550.0万
-
财政年份:2020
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
Mentoring in Clinical Pharmacology and Early Phase Trials
-
批准号:10394817
-
项目类别:
-
资助金额:$17.77万
-
财政年份:2019
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
Mentoring in Clinical Pharmacology and Early Phase Trials
-
批准号:10620632
-
项目类别:
-
资助金额:$17.77万
-
财政年份:2019
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
Global Pediatric Clinical Trials Network
-
批准号:10206152
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2017
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
Global Pediatric Clinical Trials Network
-
批准号:9980849
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2017
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
Physiologically-Based Pharmacokinetic Models for Optimal Drug Dosing in Children
-
批准号:8661919
-
项目类别:
-
资助金额:$62.14万
-
财政年份:2014
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
Physiologically-Based Pharmacokinetic Models for Optimal Drug Dosing in Children
-
批准号:8901251
-
项目类别:
-
资助金额:$67.69万
-
财政年份:2014
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
Clinical Practice Data to Aid Narrow Therapeutic Index Drug Classification
-
批准号:8890533
-
项目类别:
-
资助金额:$24.99万
-
财政年份:2013
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
Clinical Practice Data to Aid Narrow Therapeutic Index Drug Classification
-
批准号:8662573
-
项目类别:
-
资助金额:$24.7万
-
财政年份:2013
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
Pharmacokinetics and Pharmacodynamics of Antibiotics in Premature Infants
-
批准号:8514953
-
项目类别:
-
资助金额:$12.0万
-
财政年份:2010
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
Pharmacokinetics and Pharmacodynamics of Antibiotics in Premature Infants
-
批准号:8129823
-
项目类别:
-
资助金额:$11.83万
-
财政年份:2010
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
Pharmacokinetics and Pharmacodynamics of Antibiotics in Premature Infants
-
批准号:8305685
-
项目类别:
-
资助金额:$12.07万
-
财政年份:2010
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
Pharmacokinetics and Pharmacodynamics of Antibiotics in Premature Infants
-
批准号:7872599
-
项目类别:
-
资助金额:$11.55万
-
财政年份:2010
-
负责人:Michael Cohen-Wolkowiez
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: